CERebrolysine Effect on Blood-brain Barrier in acUte Ischemic Stroke

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 350 participants.

Also called NCT06078215

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 350 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06078215
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Poland (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06078215. Randomized; no masking; primary purpose treatment. Start 2023-01-10 (actual); primary completion 2025-01-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
CERebrolysine Effect on Blood-brain Barrier in acUte Ischemic Stroke
Acronym
CERBERUS
Condition
Acute Ischemic Stroke
Intervention (Combination product)
Cerebrolysin
Lead sponsor
Poznan University of Medical Sciences (class: other)

Record details

Record id
cardio:ct-nct06078215
Content hash
1112ea84c9dd8bb3ea48f4221b94a86f26e798aa28d686157d866e6717261b87